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mental study reported by Messas and col-
leagues.1 Yet from a pathophysiologic
perspective, the conclusions provided by
this study remain open to criticism. More-
over, this study is based on Kunzelman and
Cochran’s3 in vitro study of mechanical
characteristics between primary and sec-
ondary chordae, which found a greater
amount of stress borne by primary chordae
than by secondary chordae. Thus, Kunzelman
and Cochran’s statements were challenged by
the in vivo investigation of Lomholt and col-
leagues,4 which demonstrated that second-
ary chordae are more important mediators
of the valvular–ventricular interaction than
primary chordae, and that cutting second-
ary chordae adversely impairs left ventric-
ular systolic pump performance.
Finally, we would stress that each strut
chorda belongs to a given functional unit
(Figure 1), anterior or posterior papillary
muscle complexes (PMCs). Thus, it is
mandatory to determine which PMC is in-
volved predominantly in the tenting pro-
cess, or in other words, the culprit strut
chorda should be individualized. In our
opinion, the management of mechanical
imbalance between 2 PMCs resulting in
leaflet tethering should be assumed by a
selective restoration of the geometric rela-
tionships of the culprit PMC according to
the annular plan5 rather than by suppress-
ing the principal mediators of valvular–
ventricular continuity.
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Reply to the Editor:
Dr Aazami offered several criticisms of our
work:
First, the chordal cutting approach was
associated with the coronary artery bypass
graft (CABG) procedure. The rationale for
that is widely documented. Indeed, several
reports have demonstrated that residual mi-
tral regurgitation (MR) after CABG is as-
sociated with more frequent episodes of
severe angina and more severe symptoms
of heart failure.1-3 The SAVE study (Sur-
vival And Ventricular Enlargement) sug-
gested that mild ischemic MR was associ-
ated with high mortality.4 In addition,
Trichon and colleagues5 suggested that
CABG plus mitral valve surgery might be a
superior strategy in the appropriate patient
population. Thus, it is obvious from our
point of view that chordal cutting should be
performed in every single patient with
chronic ischemic MR and coronary lesions.
We believe that this reported case strongly
demonstrates the importance of combined
medical and surgical treatment of ischemic
MR and shows the value of preoperative
evaluation of the degree of MR on exercise
echocardiography to unmask severe MR
(Figure 1, A and B).
Second, we have found that preoperative
transesophageal echocardiography per-
formed by reliable and experienced hands
provides complete and reliable information
regarding mitral valve dysfunction, preoper-
atively guiding our surgical strategy. Al-
though the superior left atrial approach might
be an effective one, in our experience, when
MR was found to be due to a restrictive
mechanism with a tenting phenomenon of the
anterior mitral valve leaflet, the aortotomy
approach always provided direct and excel-
lent access to the basal chordae attached to
the center of the anterior leaflet. Four proce-
dures have been done so far using this tech-
nique. We did not encounter any mitral an-
Figure 1. A and B, Preoperative 2-dimensional echo analysis. A, Anterior leaflet angu-
lation at the basal chord insertion with apical tenting relative to the annulus, bent
anterior to the leaflet base, and moderate MR at rest. B, Severe MR on exercise. C and
D, Follow-up 2-dimensional echo analysis. C, Normal mitral coaptation at the baseline
without anterior leaflet bend or color Doppler MR despite important left ventricular
dilatation. D, Mild MR on exercise.
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nulus distortion or perioperative morbidity as
reported by Dr Aazami.
Although the findings of Lomhlot and
associates6 contradict the statements of Kun-
zelman and Cochran,7 the results of Messas
and colleagues8 are more consistent with the
major role of stress generated by primary
chordae in comparison with the secondary
ones. In addition, the intact marginal chordae
continue to prevent leaflet prolapse or failure
and can, theoretically, continue to maintain
left ventricular function through chordal con-
tinuity as a benefit of valve repair as opposed
to replacement.9,10 In our experience, the
chordal cutting procedure did not impair the
midterm (3 years’ follow-up) left ventricular
function, as shown by the absence of MR at
rest and mild MR on exertion (Figure 1, C
and D).
Finally, this report has reopened the de-
bate regarding a very difficult question that
continually challenges cardiologists and sur-
geons. Indeed, the optimal surgical treatment
of ischemic MR in patients with varying de-
grees of MR and coronary artery disease is
controversial. The complex pathophysiology
and heterogeneous clinical presentation of
this group of patients could be an explanation
for this controversy. The answer could be
provided by wide, controlled, randomized
studies comparing CABG associated with
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aortic valve replacement with
bioprostheses: Time to abandon it?
To the Editor:
According to the American College of
Cardiology/American Heart Association
(ACC/AHA) Guidelines for Valvular Heart
Disease,1 a 3-month-long program of anti-
coagulation therapy is recommended after
valve replacement with tissue valves. On
the contrary, a recent study carried out by
the Cardiothoracic Surgery Network (CTS-
Net) Valve Technology Center, “The An-
ticoagulation Therapy and Valve Replace-
ment Study,”2 has outlined that the practice
tends to diverge from the widely estab-
lished guidelines. In fact, 80% of 726 par-
ticipating surgeons prefer to adopt anti-
platelet therapy in biologic valve recipients
who do not have additional risk factors for
thromboembolic events.
Sundt and associates3 have demon-
strated in 624 patients that anticoagulant
therapy after aortic valve replacement
(AVR) did not offer advantages in terms of
neurologic morbidity compared with 527
patients who did not receive warfarin.
Similarly, at our institution, the policy
currently adopted is to administer aspirin
despite warfarin during the 3-month time
interval necessary for the sewing ring to
become completely endothelialized. Anti-
coagulants remain indicated in the presence
of comorbidities that leave the patient at
risk for thromboembolism, such as chronic
atrial fibrillation, atriomegaly, severe im-
pairment of left ventricular function, and
ventricular aneurysms.
Nevertheless, we share the concerns
raised by the CTSNet. In fact, currently
there is no clear evidence that this alterna-
tive approach is free from neurologic det-
rimental effects. We believe that the satis-
factory clinical results in terms of
cerebrovascular accidents reported by
Sundt and coworkers3 cannot exclude the
possibility of asymptomatic microemboli-
zation and that mere clinical evaluation
might be limited.
At our institution, to overcome a potential
underestimation related to sheer clinical ob-
servations, we decided to evaluate the occur-
rence of microembolic signals (MES) in pa-
tients after heart valve replacement surgery
by transcranial Doppler. Our preliminary re-
sults in 58 patients (43 men and 15 women,
mean age 69.8 years) undergoing tissue valve
replacement (23 patients) versus mechanical
valve replacement (35 patients) let us draw a
correlation between the absence of clinical
neurologic impairment (0% of neurologic
complications) and the absence of MES in
the subcohort of aortic biologic valve patients
who received aspirin instead of warfarin in
the early postoperative period (0% of MES at
transcranial Doppler). On the basis of these
preliminary results, we set out on a prospec-
tive clinical trial randomizing patients, after
AVR, for antiplatelet versus anticoagulant
early therapy. The postoperative evaluation
pursued in the trial, which is ongoing, is both
clinical and instrumental, aiming to detect
potential clinically silent microembolization.
We believe that the positive clinical re-
sults encountered by Sundt and associates3
and shared also by our experience need
instrument-based evidence to represent a
firm basis and efficacious stimulus toward
reconsideration of guidelines.
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